ICVTS Click here to locate an Ethicon representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Interact CardioVasc Thorac Surg 2006;5:488-492. doi:10.1510/icvts.2006.134387
© 2006 European Association of Cardio-Thoracic Surgery
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Douglas West
Joel Dunning
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by West, D.
Right arrow Articles by Dunning, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by West, D.
Right arrow Articles by Dunning, J.
Related Collections
Right arrow Lung - cancer
Right arrow Education

Best evidence topic - Thoracic general

Chemotherapy following complete resection of non-small-cell lung cancer is of small but significant benefit in terms of survival

Douglas Westa, Alan J.B. Kirkb and Joel Dunningc,*

a Department of Cardiothoracic Surgery, The Royal Hospital for Sick Children, Dalnair Street, Glasgow, G3 8SJ, UK
b Department of Cardiothoracic Surgery, The Western Infirmary, Glasgow, UK
c Department of Cardiothoracic Surgery, James Cook University Hospital, Middlesbrough, UK

*Corresponding author. Tel./fax: +44-7801548122.

E-mail address: joeldunning{at}doctors.org.uk (J. Dunning).

A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was whether patients benefit in terms of survival from chemotherapy following complete resection of non-small-cell lung cancer. Altogether 681 papers were found using the reported search, of which 14 represented the best evidence on this topic. The authour, journal, date and country of publication, patient group studied, study type, relevant outcomes, results and study weaknesses were tabulated. We conclude that post-operative adjuvant chemotherapy carries a small survival benefit in those patients with complete resection of their lung cancer. This survival benefit is in the region of a 4% absolute survival advantage at 5 years. Thus, 25 patients require chemotherapy to save one life at 5 years. This should be discussed with all the patients following complete resection of non-small-cell lung cancer.

Key Words: Evidence based medicine; Lung neoplasms; Antineoplastic agents; Survival; Thoracic surgery

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 European Association for Cardio-thoracic Surgery